Table 1

Prevalence of HERV-K10 antibodies among patients with testicular cancer and controls

Group (no. tested)aHERV-K10 antibody prevalence
Env antibodies (%)Gag antibodies (%)Env or Gag (%)
IndeterminatePositiveIndeterminatePositivePositiveb
Testicular cancer (30)316 (59%)76 (23%)17 (63%)
 By HIV status
  HIV positive (6)02 (33%)002 (33%)
  HIV negative (24)314 (67%)76 (35%)15 (71%)
 By histopathology
  Seminoma (19)010 (53%)33 (19%)11 (58%)
  Teratocarcinoma (6)03 (50%)01 (17%)3 (50%)
  Embryonal carcinoma (5)03 (60%)12 (50%)3 (60%)
Controls
 All groups (84)73 (4%)71 (1%)4 (5%)
  By group
   AIDS controls (21)c10100
   HIV-positive controls (19)c31 (6%)301 (6%)
   HIV-negative controls (8)1011 (14%)1 (14%)
   Cancer-prone families (16)21 (7%)201 (7%)
   Male blood donors (20)01 (5%)001 (5%)
  • a Only 30 of the 52 testicular cancer cases had specimens collected between 180 days before and 30 days after the date of diagnosis. Longitudinal results that included data from all 52 cases are presented in the text. HIV-positive controls included 39 homosexual men and one man with hemophilia. HIV-negative controls were all homosexual men. Cancer-prone families included renal adenocarcinoma cases and their first-degree relatives, as well as first-degree relatives of testicular cancer cases (10 , 11) .

  • b For overall prevalence estimates, samples were excluded only if both Env and Gag results were indeterminate.

  • c AIDS defined as HIV positive with CD4+ lymphocyte count <150 cells/μl. Other HIV-positive controls had higher CD4+ lymphocyte counts at the time of phlebotomy.